ADAR1 Capital Management LLC Buys 723,933 Shares of Zura Bio Limited $ZURA

Key Points

• ADAR1 Capital Management LLC increased its stake in Zura Bio Limited by 34.9%, owning 4.10% of the company after acquiring 723,933 shares in the first quarter.
• Zura Bio reported earnings of ($0.17) EPS for the last quarter, surpassing analysts' expectations of ($0.19) by $0.02.
• Analysts currently hold a consensus rating of "Buy" for Zura Bio, with a consensus price target of $14.00 despite Oppenheimer and HC Wainwright lowering their price targets recently.

ADAR1 Capital Management LLC raised its holdings in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 34.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,801,184 shares of the company's stock after buying an additional 723,933 shares during the quarter. ADAR1 Capital Management LLC owned about 4.10% of Zura Bio worth $3,614,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Two Sigma Advisers LP acquired a new position in Zura Bio in the 4th quarter valued at approximately $32,000. ProShare Advisors LLC acquired a new position in shares of Zura Bio in the fourth quarter valued at $35,000. Wells Fargo & Company MN lifted its position in Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock worth $58,000 after purchasing an additional 9,379 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Zura Bio in the 4th quarter valued at $62,000. Finally, Nuveen LLC acquired a new position in shares of Zura Bio in the 1st quarter valued at $76,000. Institutional investors and hedge funds own 61.14% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ZURA. Chardan Capital restated a "buy" rating and set a $10.00 target price on shares of Zura Bio in a research report on Friday, August 15th. Oppenheimer dropped their price objective on Zura Bio from $17.00 to $16.00 and set an "outperform" rating for the company in a research note on Friday, August 15th. Finally, HC Wainwright reduced their target price on shares of Zura Bio from $3.00 to $2.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $14.00.

Zura Bio Stock Performance

Shares of NASDAQ ZURA traded up $0.13 during trading on Friday, reaching $2.20. The company had a trading volume of 368,595 shares, compared to its average volume of 341,619. The stock has a market cap of $143.04 million, a PE ratio of -3.14 and a beta of -0.02. The business's 50 day moving average price is $1.61 and its 200-day moving average price is $1.36. Zura Bio Limited has a 52 week low of $0.97 and a 52 week high of $5.07.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.02. Equities analysts anticipate that Zura Bio Limited will post -0.65 earnings per share for the current year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.